- Home
- DGHI vs DYAI Comparison
DGHI vs DYAI Comparison
Compare DGHI & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGHI
- DYAI
- Stock Information
- Founded
- DGHI 2017
- DYAI 1979
- Country
- DGHI United States
- DYAI United States
- Employees
- DGHI N/A
- DYAI N/A
- Industry
- DGHI Finance: Consumer Services
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGHI Finance
- DYAI Health Care
- Exchange
- DGHI Nasdaq
- DYAI Nasdaq
- Market Cap
- DGHI 32.6M
- DYAI 31.5M
- IPO Year
- DGHI N/A
- DYAI 2004
- Fundamental
- Price
- DGHI $1.92
- DYAI $1.14
- Analyst Decision
- DGHI Strong Buy
- DYAI Strong Buy
- Analyst Count
- DGHI 1
- DYAI 1
- Target Price
- DGHI $2.50
- DYAI $6.00
- AVG Volume (30 Days)
- DGHI 271.0K
- DYAI 17.1K
- Earning Date
- DGHI 11-15-2024
- DYAI 11-12-2024
- Dividend Yield
- DGHI N/A
- DYAI N/A
- EPS Growth
- DGHI N/A
- DYAI N/A
- EPS
- DGHI N/A
- DYAI N/A
- Revenue
- DGHI $38,327,380.00
- DYAI $3,364,548.00
- Revenue This Year
- DGHI N/A
- DYAI $2.04
- Revenue Next Year
- DGHI N/A
- DYAI $110.34
- P/E Ratio
- DGHI N/A
- DYAI N/A
- Revenue Growth
- DGHI 97.65
- DYAI 13.82
- 52 Week Low
- DGHI $0.84
- DYAI $0.93
- 52 Week High
- DGHI $2.54
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- DGHI 61.73
- DYAI 53.97
- Support Level
- DGHI $1.60
- DYAI $1.02
- Resistance Level
- DGHI $2.20
- DYAI $1.15
- Average True Range (ATR)
- DGHI 0.25
- DYAI 0.08
- MACD
- DGHI 0.04
- DYAI 0.01
- Stochastic Oscillator
- DGHI 65.96
- DYAI 93.38
About DGHI Digihost Technology Inc. Common Subordinate Voting Shares
Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.